Global clinical development on Dengue antiviral candidate will start, Hyundai Bioscience strives to win emergency use authorization

SEOUL, South Korea, April 18, 2024 /PRNewswire/ — South Korea’s biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection. “The…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.